Russ Conroy

Articles

Isa-KRd Yields Prolonged MRD Negativity vs KRd in Newly Diagnosed Myeloma

June 16th 2025

Isa-KRd significantly improved the 1-year MRD negativity rate compared with KRd alone in newly diagnosed patients with multiple myeloma.

JNJ’4496 Shows Preliminary Efficacy and Safety in Relapsed/Refractory LBCL

June 13th 2025

JNJ’4496 demonstrated an ORR of 100% in patients with relapsed or refractory large B-cell lymphoma who received 1 prior line of treatment.

Iptacopan Shows Efficacy Improvements Over Anti-C5 Therapy in Previously Treated Paroxysmal Nocturnal Hemoglobinuria

June 13th 2025

Oral iptacopan monotherapy led to hemoglobin level and transfusion independence benefits vs anti-C5 therapies in paroxysmal nocturnal hemoglobinuria.

Revumenib-Based Triplet Is Safe, Highly Active in Older/Unfit NPM1/KMT2A-Altered AML

June 12th 2025

Revumenib plus azacitidine and venetoclax yielded high CR rates among older patients with NPM1-mutant/KMT2A-rearranged newly diagnosed AML.

RET Inhibitor Rechallenge Demonstrates Activity in Previously Treated NSCLC

June 8th 2025

RET rechallenge following disease progression demonstrated greater efficacy with select combination therapies targeting bypass resistance vs single agents.

SC Daratumumab Plus VRd Displays Durable Efficacy in Newly Diagnosed, Transplant-Eligible Myeloma

June 3rd 2025

Daratumumab plus VRd continued to demonstrate improvements in MRD negativity and PFS in newly diagnosed, transplant-ineligible multiple myeloma.

COCOON DM Regimen Reduces Amivantamab/Lazertinib Effects on QOL in EGFR-Mutated NSCLC

June 2nd 2025

COCOON DM reduced the severity and QOL influence of dermatologic AEs vs SOC DM in EGFR-mutant, advanced NSCLC treated with amivantamab plus lazertinib.

D-VRd Retains Its Role as a Potential Standard of Care for Transplant-Ineligible Multiple Myeloma

June 2nd 2025

D-VRd led to deeper and more durable responses that translated into improved PFS vs VRd alone in transplant-ineligible patients with multiple myeloma.

First-Line T-DXd Plus Pertuzumab Yields PFS Benefit in HER2+ Advanced Breast Cancer

June 2nd 2025

Trastuzumab deruxtecan plus pertuzumab produced a statistically significant PFS improvement in frontline HER2-positive advanced breast cancer.

Sacituzumab Govitecan Plus Pembrolizumab Displays Activity in Early-Stage TNBC

June 1st 2025

Sacituzumab govitecan in combination with pembrolizumab led to pathologic complete responses in early-stage triple-negative breast cancer.

Glofitamab/GemOx Enhances OS and PFS vs Rituximab in R/R DLBCL

June 1st 2025

Glofitamab plus gemcitabine/oxaliplatin demonstrated improved PFS and OS compared with rituximab in patients with relapsed/refractory DLBCL.

Indirect Comparisons Shows Relatlimab/Nivolumab Has Comparable Outcomes to Ipilimumab/Nivolumab in Advanced Melanoma

June 1st 2025

The efficacy of relatlimab/nivolumab was consistent across patient subgroups vs ipilimumab/nivolumab in advanced melanoma.

Zanubrutinib Plus Venetoclax Yields High Response Rates in Treatment-Naive CLL/SLL

May 31st 2025

Zanubrutinib in combination with venetoclax was highly active in patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Sotorasib/Panitumumab Resistance May Be Linked to Genomic Alterations in KRAS G12C+ mCRC

May 31st 2025

Treatment resistance to sotorasib plus panitumumab may stem from genomic alterations in KRAS G12C–mutated CRC.

Prospective, Real-World Study Highlights Feasibility of Outpatient Robotic Partial Nephrectomy in Renal Tumors

April 29th 2025

A high proportion of patients with renal tumors were discharged on the same day after receiving robotic partial nephrectomy.

Retrospective Study Shows Variability of Interventions for Blinatumomab-Related Neurotoxicity in Hematologic Malignancies

April 11th 2025

A retrospective study found that interventions for patients experiencing grade 2 vs 3 blinatumomab-associated ICANS were not consistently implemented.

Rina-S Generates Durable Responses in Advanced Platinum-Resistant Ovarian Cancer

March 17th 2025

The median DOR with Rina-S was not reached and the treatment was well tolerated in patients with FRα-unselected platinum-resistant ovarian cancer.

Zimberelimab Plus Lenvatinib Shows Activity in ICI-Pretreated Advanced Cervical Cancer

March 15th 2025

The combination of zimberelimab and lenvatinib had antitumor activity and a manageable safety profile in pretreated advanced cervical cancer.

Afuresertib Plus Paclitaxel Does Not Elicit Substantial Clinical Benefit in Platinum-Resistant Ovarian Cancer

March 15th 2025

Afuresertib combined with paclitaxel did not elicit PFS or OS benefits vs paclitaxel alone in patients with unselected platinum-resistant ovarian cancer.

Olaparib After Durvalumab/Chemo Boosts PFS in Subgroups of pMMR Endometrial Cancer

March 15th 2025

Olaparib maintenance following durvalumab plus chemotherapy improved PFS in different subgroups of pMMR endometrial cancer.